These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2016946)

  • 1. [Treatment of hypertension in Sweden: treatment of patients with hypertension costs more than a billion crowns per year].
    Johannesson M; Borgqvist L; Jönsson B; Råstam L
    Lakartidningen; 1991 Mar; 88(12):1103-6. PubMed ID: 2016946
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of hypertension at a health center. 1: The drugs prescribed for men are much more expensive than the ones prescribed for women].
    Johannesson M; Borgquist L; Elenstål A; Jönsson B; Tilling B
    Lakartidningen; 1991 Mar; 88(12):1096-8. PubMed ID: 2016944
    [No Abstract]   [Full Text] [Related]  

  • 3. [What is the cost of hypertension treatment to society?].
    Aberg H
    Lakartidningen; 1991 Mar; 88(12):1055-6. PubMed ID: 2016931
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of hypertension at a health center. 2: The patients' expenses in connection with transport and time are more than a tenth of the total treatment costs].
    Johannesson M; Borgquist L; Elenstål A; Jönsson B; Tilling B
    Lakartidningen; 1991 Mar; 88(12):1098, 1100-1, 1103. PubMed ID: 2016945
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
    Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
    Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Consumption of antihypertensive drugs and costs of treatment of arterial hypertension at a Swiss medical polyclinic (1975-1985)].
    Graf F; Knorr M; Siegenthaler W; Vetter W
    Schweiz Rundsch Med Prax; 1986 Apr; 75(14):378-84. PubMed ID: 3961350
    [No Abstract]   [Full Text] [Related]  

  • 7. Changing prescription patterns: impact on costs.
    Bock KD
    J Hypertens Suppl; 1987 Aug; 5(3):S83-5. PubMed ID: 3478431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New guidelines for the treatment of hypertension--what has really happened since the last time?].
    Hjemdahl P
    Lakartidningen; 1990 Sep; 87(39):3068-9. PubMed ID: 2215021
    [No Abstract]   [Full Text] [Related]  

  • 9. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
    Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
    Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
    [No Abstract]   [Full Text] [Related]  

  • 10. Trends in antihypertensive medication costs in a cohort of Aucklanders 1982-87.
    Sinclair BL; Ashton T; Jackson R; Beaglehole R
    N Z Med J; 1989 Oct; 102(877):521-3. PubMed ID: 2797584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment.
    Johannesson M
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S23-6. PubMed ID: 8868040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension.
    Doyle J; Omvik P; Arikian S; Casciano J; Casciano R; Gonzalez MA; Arocho R
    Manag Care Interface; 2001 Mar; 14(3):82-7. PubMed ID: 11301961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical economics of hypertension therapy].
    Yamazaki T
    Nihon Rinsho; 2008 Aug; 66(8):1601-4. PubMed ID: 18700564
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of antihypertensive drugs in Spain (1995-2001)].
    García del Pozo J; Ramos Sevillano E; de Abajo FJ; Mateos Campos R
    Rev Esp Cardiol; 2004 Mar; 57(3):241-9. PubMed ID: 15056428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health insurance status and hypertension monitoring and control in the United States.
    Duru OK; Vargas RB; Kermah D; Pan D; Norris KC
    Am J Hypertens; 2007 Apr; 20(4):348-53. PubMed ID: 17386339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
    Wilson TW; Chockalingam A; Quest DW
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin receptor blockers: impact on costs of care.
    Am J Manag Care; 2005 Nov; 11(13 Suppl):S400-3. PubMed ID: 16300456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension control: improved, but not enough!
    Alderman MH
    Am J Hypertens; 2007 Apr; 20(4):347. PubMed ID: 17386338
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost implications of development of diabetes in the ALPINE study.
    Lindholm LH; Kartman B; Carlberg B; Persson M; Svensson A; Samuelsson O
    J Hypertens Suppl; 2006 Mar; 24(1):S65-72. PubMed ID: 16601576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.